Ovid Therapeutics Inc. (OVID)
D
Pipeline Grade
Financial Position (from SEC Filings)
$96.0M
Cash & Equivalents
$13.9M
Quarterly Burn Rate
21 mo
Est. Cash Runway
$470M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-08-01 | Phase3 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06809595 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | PHASE3 | Active Not Recruiting | 245 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.